European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 12, 2015, Pages 2277-2294

  Nast, A ^a   Gisondi, P ^b   Ormerod, A D ^c   Saiag, P ^d   Smith, C ^e   Spuls, P I ^f   Arenberger, P ^g   Bachelez, H ^h   Barker, J ^e   Dauden, E ⁱ   De Jong, E M ^j   Feist, E ^a   Jacobs, A ^a   Jobling, R ^k   Kemeny L ^l   Maccarone, M ^m   Mrowietz, U ⁿ   Papp, K A ^m   Paul, C ^o   Reich, K ^p   Rosumeck, S ^a   Talme, T ^q   Thio, H B ^r   Van De Kerkhof, P ^j   Werner, R N ^a   Yawalkar, N ^s   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF VERONA   (Italy)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d HÔPITAL AMBROISE PARÉ   (France)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g CHARLES UNIVERSITY   (Czech Republic)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Cambridge ESOL   (United Kingdom)

^l SZTE Borgyogyaszati Klinika   (Hungary)

^m University Medical Center Schleswig Holstein ^*  (Canada)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o UNIVERSITÉ PAUL SABATIER   (France)

^p Dermatologikum Hamburg   (Germany)

^q KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^r ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^s UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ETRETIN; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; FUMARIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; KERATOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DIABETES MELLITUS; DRUG INDICATION; EUROPE; HEPATITIS; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; LYMPHOMA; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; SKIN CANCER; TUBERCULOSIS; COMBINATION DRUG THERAPY; PSORIASIS;

ACITRETIN; ADALIMUMAB; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ETANERCEPT; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOLYTIC AGENTS; METHOTREXATE; PSORIASIS; USTEKINUMAB;

EID: 84959346114     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13354     Document Type: Review

References (7)

1. Atkins D, Best D, Briss PA, et al,. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
2. Jones J, Hunter D,. Consensus methods for medical and health services research. BMJ 1995; 311: 376-380.
3. Murphy E, Black N, Lamping D, McKee C, Sanderson C,. Consensus development methods, and their use in clinical guideline development: a review. Health Technol Assess 1998; 2: 88.
4. Andrews JC, Schunemann HJ, Oxman AD, et al,. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013; 66: 726-735.
5. Andrews J, Guyatt G, Oxman AD, et al,. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725.
6. European Medicines Agency. CHMP summary of positive opinion for Cosentyx [Secukinumab]. 2014. Available at: http://www.ema.europa.eu:80/ema/index.jsp?curl=pages/medicines/human/medicines/003729/smops/Positive/human-smop-000755.jsp&mid=WC0b01ac058001d127 (last accessed: February 20, 2015).
7. European Medicines Agency. CHMP summary of positive opinion for Otezla [Apremilast]. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003746/smops/Positive/human-smop-000754.jsp&mid=WC0b01ac058001d127 (last accessed: February 20, 2015).